Connect Biopharma Holdings Ltd (CNTB) stock
CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.67+0.09 (+14.93%)
Close on Nov 18, 2026Market cap $41.89MP/E –Yield –
Connect Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Connect Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$70.41M. For fiscal 2025 it was -$58.07M. The highest annual figure on record is -$22.45M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.07M | – |
| FY2024 | Dec 31, 2024 | -$22.45M | – |
| FY2023 | Dec 31, 2023 | -$69.06M | – |
| FY2022 | Dec 31, 2022 | -$119.32M | – |
| FY2021 | Dec 31, 2021 | -$98.11M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.42M | -198.4% |
| Q1 FY2025 | Mar 31, 2025 | -$11.45M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.85M | – |
| Q2 FY2024 | Jun 30, 2024 | $13.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.63M | – |
See a number that looks wrong?